Eli Lilly Stock News

Eli Lilly stock (NYSE: LLY) has seen phenomenal gains of 345% from levels of $170 in early January 2021 to around $755 now, vs. an increase of about 35% for the S&P 500 over this roughly three-year pe

Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.

Growth stocks are rising, offering stellar gains so far this year. The tech-heavy S&P 500 continues to post new highs, with investors shrugging off inflation concerns.

Iovance Biotherapeutics just got a cell therapy for melanoma approved. The medicine will likely be very costly to make and deliver to patients.

Investors need not be concerned about the FDA's approval delay for Eli Lilly's Alzheimer's drug. Novo Nordisk recently picked up a regulatory win that makes the stock even more attractive.

Sales of new highly effective weight management treatments are soaring. Eli Lilly entered the weight management arena after its main rival, Novo Nordisk, but clinical trial results suggest its drug co

There are only six trillion-dollar stocks worldwide, every one of which is a popular name. And they all rightfully sit at the top of their sectors.

Eli Lilly is facing a major delay with its latest Alzheimer's program. Regulators are bringing in outside experts to review its approval request.

Eli Lilly recently selected Amazon Pharmacy to fill online prescriptions for its LillyDirect platform. This partnership benefits both Lilly and Amazon.

Eli Lilly's powerful weight-loss drug Zepbound hit 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk's rival obesity medicine Wegovy for the first time since it

JP Morgan is hiking Eli Lilly's price target to $850. The Investment Committee debate it.

Eli Lilly has a huge opportunity in the anti-obesity market to generate tens of billions in revenue. The big battle could be over which company develops the best weight-loss drug.

When many investors hear the word mania, they may think of artificial intelligence (AI) stocks or Bitcoin. Both investments have yielded market-beating returns and have room to run higher.

Pfizer's pipeline already includes two obesity drugs. However, doubts about Pfizer's lead obesity program could make buying Viking a smart move.

Eli Lilly (LLY) partners with Amazon Pharmacy to help deliver its obesity, migraine and diabetes drugs, including Zepbound.